Clinical Research Directory

Inclusion Criteria: * Patient aged 18 to 37 year-old; * Patients with a BMI below 34 kg/m2; * After a fresh embryo transfer following an ovarian hyperstimulation for an IVF with a luteal phase support based on micronized vaginal progesterone; * With a positive pregnancy test (bhCG \> 100 UI/L); * With a serum progesterone level below 17 ng/mL on the day of pregnancy test; * Patient able to self-administer subcutaneous progesterone injections, either alone or with the help of her partner. Exclusion Criteria: * Patient undertaking an additional source of progesterone (oral or injected) or a treatment stimulating endogenous progesterone secretion (such as GnRH agonist or hCG injections); * Patients with intolerance or contraindication to subcutaneous progesterone administration; * Patients with a known 21-hydroxylase deficiency; * Patients with uterine pathology or untreated hydrosalpinx; * Patients with a history of recurrent miscarriages (3 or more); * Patient undergoing pre-implantation genetic testing; * Patient unavailable or unwilling to participate in future visits or is unable to comply with trial protocol; * Subjects unable to read or/and write French; * Failure to obtain the consent; * Subjects non-beneficiary of the French social security (Government medical aid (AME) excluded); * Subjects placed under legal protection, under guardianship or under curatorship; * Patient in an exclusion period determined by a previous study; * Subjects participating in another interventional research.